167 related articles for article (PubMed ID: 23430838)
1. The molecular landscape of phosphomannose mutase deficiency in iberian peninsula: identification of 15 population-specific mutations.
Pérez B; Briones P; Quelhas D; Artuch R; Vega AI; Quintana E; Gort L; Ecay MJ; Matthijs G; Ugarte M; Pérez-Cerdá C
JIMD Rep; 2011; 1():117-23. PubMed ID: 23430838
[TBL] [Abstract][Full Text] [Related]
2. Expression analysis revealing destabilizing mutations in phosphomannomutase 2 deficiency (PMM2-CDG): expression analysis of PMM2-CDG mutations.
Vega AI; Pérez-Cerdá C; Abia D; Gámez A; Briones P; Artuch R; Desviat LR; Ugarte M; Pérez B
J Inherit Metab Dis; 2011 Aug; 34(4):929-39. PubMed ID: 21541725
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and molecular studies in 26 Spanish patients with congenital disorder of glycosylation type Ia.
Briones P; Vilaseca MA; Schollen E; Ferrer I; Maties M; Busquets C; Artuch R; Gort L; Marco M; van Schaftingen E; Matthijs G; Jaeken J; Chabás A
J Inherit Metab Dis; 2002 Dec; 25(8):635-46. PubMed ID: 12705494
[TBL] [Abstract][Full Text] [Related]
4. The Effects of PMM2-CDG-Causing Mutations on the Folding, Activity, and Stability of the PMM2 Protein.
Yuste-Checa P; Gámez A; Brasil S; Desviat LR; Ugarte M; Pérez-Cerdá C; Pérez B
Hum Mutat; 2015 Sep; 36(9):851-60. PubMed ID: 26014514
[TBL] [Abstract][Full Text] [Related]
5. Congenital disorder of glycosylation type Ia: searching for the origin of common mutations in PMM2.
Quelhas D; Quental R; Vilarinho L; Amorim A; Azevedo L
Ann Hum Genet; 2007 May; 71(Pt 3):348-53. PubMed ID: 17166182
[TBL] [Abstract][Full Text] [Related]
6. Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG.
Iyer S; Sam FS; DiPrimio N; Preston G; Verheijen J; Murthy K; Parton Z; Tsang H; Lao J; Morava E; Perlstein EO
Dis Model Mech; 2019 Nov; 12(11):. PubMed ID: 31636082
[TBL] [Abstract][Full Text] [Related]
7. Yeast Models of Phosphomannomutase 2 Deficiency, a Congenital Disorder of Glycosylation.
Lao JP; DiPrimio N; Prangley M; Sam FS; Mast JD; Perlstein EO
G3 (Bethesda); 2019 Feb; 9(2):413-423. PubMed ID: 30530630
[TBL] [Abstract][Full Text] [Related]
8. The Prevalence of PMM2-CDG in Estonia Based on Population Carrier Frequencies and Diagnosed Patients.
Vals MA; Pajusalu S; Kals M; Mägi R; Õunap K
JIMD Rep; 2018; 39():13-17. PubMed ID: 28685491
[TBL] [Abstract][Full Text] [Related]
9. A new insight into PMM2 mutations in the French population.
Le Bizec C; Vuillaumier-Barrot S; Barnier A; Dupré T; Durand G; Seta N
Hum Mutat; 2005 May; 25(5):504-5. PubMed ID: 15844218
[TBL] [Abstract][Full Text] [Related]
10. Genotypes and estimated prevalence of phosphomannomutase 2 deficiency in Turkey differ significantly from those in Europe.
Yıldız Y; Arslan M; Çelik G; Kasapkara ÇS; Ceylaner S; Dursun A; Sivri HS; Coşkun T; Tokatlı A
Am J Med Genet A; 2020 Apr; 182(4):705-712. PubMed ID: 31981409
[TBL] [Abstract][Full Text] [Related]
11. A frequent mild mutation in ALG6 may exacerbate the clinical severity of patients with congenital disorder of glycosylation Ia (CDG-Ia) caused by phosphomannomutase deficiency.
Westphal V; Kjaergaard S; Schollen E; Martens K; Grunewald S; Schwartz M; Matthijs G; Freeze HH
Hum Mol Genet; 2002 Mar; 11(5):599-604. PubMed ID: 11875054
[TBL] [Abstract][Full Text] [Related]
12. The Analysis of Variants in the General Population Reveals That
Citro V; Cimmaruta C; Monticelli M; Riccio G; Hay Mele B; Cubellis MV; Andreotti G
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30061496
[TBL] [Abstract][Full Text] [Related]
13. Heterodimerization of Two Pathological Mutants Enhances the Activity of Human Phosphomannomutase2.
Andreotti G; Monti MC; Citro V; Cubellis MV
PLoS One; 2015; 10(10):e0139882. PubMed ID: 26488408
[TBL] [Abstract][Full Text] [Related]
14. High residual activity of PMM2 in patients' fibroblasts: possible pitfall in the diagnosis of CDG-Ia (phosphomannomutase deficiency).
Grünewald S; Schollen E; Van Schaftingen E; Jaeken J; Matthijs G
Am J Hum Genet; 2001 Feb; 68(2):347-54. PubMed ID: 11156536
[TBL] [Abstract][Full Text] [Related]
15. Congenital disorder of glycosylation type Ia (CDG-Ia): phenotypic spectrum of the R141H/F119L genotype.
Kjaergaard S; Schwartz M; Skovby F
Arch Dis Child; 2001 Sep; 85(3):236-9. PubMed ID: 11517108
[TBL] [Abstract][Full Text] [Related]
16. Scandinavian CDG-Ia patients: genotype/phenotype correlation and geographic origin of founder mutations.
Erlandson A; Bjursell C; Stibler H; Kristiansson B; Wahlström J; Martinsson T
Hum Genet; 2001 May; 108(5):359-67. PubMed ID: 11409861
[TBL] [Abstract][Full Text] [Related]
17. Identification of four novel PMM2 mutations in congenital disorders of glycosylation (CDG) Ia French patients.
Vuillaumier-Barrot S; Hetet G; Barnier A; Dupré T; Cuer M; de Lonlay P; Cormier-Daire V; Durand G; Grandchamp B; Seta N
J Med Genet; 2000 Aug; 37(8):579-80. PubMed ID: 10922383
[TBL] [Abstract][Full Text] [Related]
18. PMM2 mutation spectrum, including 10 novel mutations, in a large CDG type 1A family material with a focus on Scandinavian families.
Bjursell C; Erlandson A; Nordling M; Nilsson S; Wahlström J; Stibler H; Kristiansson B; Martinsson T
Hum Mutat; 2000 Nov; 16(5):395-400. PubMed ID: 11058896
[TBL] [Abstract][Full Text] [Related]
19. Mild clinical and biochemical phenotype in two patients with PMM2-CDG (congenital disorder of glycosylation Ia).
Casado M; O'Callaghan MM; Montero R; Pérez-Cerda C; Pérez B; Briones P; Quintana E; Muchart J; Aracil A; Pineda M; Artuch R
Cerebellum; 2012 Jun; 11(2):557-63. PubMed ID: 22012410
[TBL] [Abstract][Full Text] [Related]
20. Lack of homozygotes for the most frequent disease allele in carbohydrate-deficient glycoprotein syndrome type 1A.
Matthijs G; Schollen E; Van Schaftingen E; Cassiman JJ; Jaeken J
Am J Hum Genet; 1998 Mar; 62(3):542-50. PubMed ID: 9497260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
